tbuckley/cabot-search huggingface dataset:
Low Frequency of MLL-PTD Detected in Pediatric Acute Myeloid Leukemia Using MLPA Screening.
Authors: Brian Balgobind, Iris H.I.M. Hollink, Dirk Reinhardt, Elisabeth R van Wering, Siebold S.N. de Graaf, Andre Baruchel, Jean-Michel Cayuela, Rob Pieters, Christian M Zwaan, Marry M van den Heuvel-Eibrink
Journal: Blood (2008)
Development of a Digital-PCR Assay for Screening and Quantitative Monitoring of Calreticulin (CALR) Type-2 Positive Patients with Myelofibrosis Following Allogeneic Stem Cell Transplantation
Authors: Boris Fehse, Anita Badbaran, Maximilian Christopeit, Tim Aranyossy, Francis Ayuk, Christine Wolschke, Nicolaus Kroeger
Journal: Blood (2015)
A Sensitized Screen Uncovers a Novel Platelet Phenotype in a Loss-of-Function Jak2 Allele.
Authors: Nicole Anderson, Mojib Javadi Javed, Monica L Bailey, Kai Huang, Zorana Berberovic, Ann Flenniken, Chen Wang, Mark D. Minden, Robert Paulson, Kelly M. McNagny, William L. Stanford, Dwayne L Barber
Journal: Blood (2009)
AB0748 Novel Biomarkers Distinguish Psoriatic Arthritis from Psoriasis
Authors: V. Chandran, D. Cretu, L. Gao, K. Liang, E.P. Diamandis
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis patients for appropriate referral to a rheumatologist. <h3>Objectives</h3> Our purpose was to investigate whether serum levels of novel markers discovered by quantitative mass spectrometry (MS) of synovial fluid and skin biopsies, differentiate PsA patients from those with psoriasis without PsA (PsC). <h3>Methods</h3> Serum samples were obtained from 100 patients with PsA, 100 with PsC, and 100 healthy controls. Subjects were group matched for age and sex. No patient was undergoing treatment with biologics at the time of serum collection. Using enzyme-linked immunosorbent assays, four high-priority markers, previously discovered by quantitative MS of synovial fluid and skin biopsies, were analyzed in the serum: Mac-2-binding protein (M2BP), CD5-like protein (CD5L), Myeloperoxidase (MPO), and Integrin-β 5 (ITGB5), as well as previously established markers Matrix metalloproteinase-3 (MMP3) and C-reactive protein (CRP). Data were analyzed using logistic regression (LR), and receiver operating characteristic (ROC) curves were plotted. <h3>Results</h3> The 100 PsA patients (41 females, mean age 51 years) had mean psoriasis duration of 22.9 years, PsA duration of 14.6 years, swollen joint count 3.2, tender joint count 6, and PASI score of 4.7. The 100 PsC patients (45 females, mean age 50 years) had mean psoriasis duration of 20.3 years and PASI score of 4. The 100 controls (52 females) had a mean age of 35 years. Polychotomous LR showed that ITGB5, CRP and M2BP are markers that are significantly different between the three groups. The analyses also showed that CD5L, ITGB5, M2BP, MPO, MMP3 and CRP are independently associated with PsA, while CD5L, M2BP and MPO are independently associated with PsC. When comparing PsA to PsC, ITGB5, M2BP, and CRP were found to be independently associated with PsA (Table 1). ROC analysis (Figure 1) of this model showed an area under the ROC curve of 0.85 (95% CI [0.80, 0.90]) that was superior to CRP only model (AUC 0.68 [0.60, 0.76]). <h3>Conclusions</h3> CD5L, ITGB5, M2BP, MPO, MMP3 and CRP are soluble PsA markers. However, only ITGB5, M2BP and CRP, differentiate PsA from PsC, and is superior to CRP alone. <h3>Acknowledgement</h3> This study was funded by Abbvie Canada. <h3>Disclosure of Interest</h3> V. Chandran Grant/research support from: Abbvie, D. Cretu: None declared, L. Gao: None declared, K. Liang: None declared, E. Diamandis: None declared
Trichoscopy of dissecting cellulitis of the scalp: Exclamation mark hairs and white dots as markers of disease chronicity
Authors: Gonzalo Segurado-Miravalles, Francisco Camacho-Martınez, Salvador Arias-Santiago, Rita Rodrigues-Barata, Cristina Serrano-Falcón, Oscar Muñoz Moreno-Arrones, Pedro Jaén Olasolo, Sergio Vañó-Galván
Journal: Journal of the American Academy of Dermatology (2016)
Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.
Authors: Benjamin M Solomon, Kari G. Rabe, Jonathan Moreira, Susan Schwager, James R Cerhan, Timothy G. Call, Neil E. Kay, Susan L Slager, Tait D. Shanafelt
Journal: Blood (2012)
RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.
Authors: Mitch Raponi, Tatiana Vener, Carlo Derecho, Jacqueline Greer, Sami Malek, John Palma, Judith E Karp
Journal: Blood (2009)
Evolution of Rosaceae Fruit Types Based on Nuclear Phylogeny in the Context of Geological Times and Genome Duplication
Authors: Yezi Xiang, Chien-Hsun Huang, Yi Hu, Jun Wen, Shisheng Li, Tingshuang Yi, Hongyi Chen, Jun Xiang, Hong Ma
Journal: Molecular Biology and Evolution (2016)

Fruits are the defining feature of angiosperms, likely have contributed to angiosperm successes by protecting and dispersing seeds, and provide foods to humans and other animals, with many morphological types and important ecological and agricultural implications. Rosaceae is a family with ∼3000 species and an extraordinary spectrum of distinct fruits, including fleshy peach, apple, and strawberry prized by their consumers, as well as dry achenetum and follicetum with features facilitating seed dispersal, excellent for studying fruit evolution. To address Rosaceae fruit evolution and other questions, we generated 125 new transcriptomic and genomic datasets and identified hundreds of nuclear genes to reconstruct a well-resolved Rosaceae phylogeny with highly supported monophyly of all subfamilies and tribes. Molecular clock analysis revealed an estimated age of ∼101.6 Ma for crown Rosaceae and divergence times of tribes and genera, providing a geological and climate context for fruit evolution. Phylogenomic analysis yielded strong evidence for numerous whole genome duplications (WGDs), supporting the hypothesis that the apple tribe had a WGD and revealing another one shared by fleshy fruit-bearing members of this tribe, with moderate support for WGDs in the peach tribe and other groups. Ancestral character reconstruction for fruit types supports independent origins of fleshy fruits from dry-fruit ancestors, including the evolution of drupes (e.g., peach) and pomes (e.g., apple) from follicetum, and drupetum (raspberry and blackberry) from achenetum. We propose that WGDs and environmental factors, including animals, contributed to the evolution of the many fruits in Rosaceae, which provide a foundation for understanding fruit evolution.
FRI0515 Quantification and Impact of Secondary Osteoarthritis in Patients with Anti-Citrullinated Protein Antibodies Positive Rheumatoid Arthritis
Authors: C.P. Figueiredo, D. Simon, M. Englbrecht, J. Haschka, A. Kleyer, S. Bayat, A.J. Hueber, R.M. Pereira, J. Rech, G. Schett
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Erosions have been described as the hallmark of bone damage in RA, resembling catabolic changes [1]. Usually bone erosions in RA are not accompanied by proliferative bone changes, which are typically found in psoriatic arthritis and spondyloarthritis [2]. Although such changes are much less pronounced in RA than in other diseases, RA patients may not be completely spared from bony proliferations, which likely resemble the development of secondary osteoarthritis. <h3>Objectives</h3> To search for evidence of secondary osteoarthritis in patients with rheumatoid arthritis (RA) in a cross-sectional and longitudinal setting and to relate osteophyte formation to functional outcome. <h3>Methods</h3> Anti-citrullinated protein antibody positive (ACPA+) RA patients underwent high-resolution peripheral quantitative computed tomography (HR-pQCT) of the hand. Cross-sectional and longitudinal measurements were performed. Number and size of osteophytes as well as bone erosions were documented. Relation of osteophytes to bone erosions and to demographic and disease specific data was evaluated by multiple logistic regression models. <h3>Results</h3> 202 ACPA+ RA patients were enrolled in the cross-sectional and 77 subjects in the longitudinal analysis (interval: 1.5 years). The mean number and size of osteophytes was 1.3±2.3 and 9.4±23.9 mm<sup>3</sup> respectively. Osteophyte number was significantly (p&lt;0.001) correlated to erosion number and osteophyte size to erosion size (p&lt;0.001). Moreover, presence and size of osteophytes were related to age (p&lt;0.001), disease duration (p&lt;0.001) and health assessment questionnaire (HAQ) (p=0.013). Multivariate regression analyses showed an independent association between osteophytes and erosions. In the longitudinal analysis the mean number (p=0.033) and size (p&lt;0.001) of osteophytes significantly increased in RA patients during their disease course (Figure 1). <h3>Conclusions</h3> Age, disease duration and bone erosions are associated with osteophytes indicating development of secondary osteoarthritis in patients with RA. <h3>References</h3> McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–63. <h3>Disclosure of Interest</h3> None declared
Time-Sequenced G-CSF (Lenograstim) for the Treatment of Adult Acute Lymphoblastic Leukemia - Seven Year Follow-Up of the Polish Adult Leukemia Group 4–96 Study.
Authors: Sebastian Giebel, Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, Slawomira Kyrcz-Krzemien, Andrzej Hellmann, Anna Dmoszynska, Monika Paluszewska, Tadeusz Robak, Lech Konopka, Ilona Seferynska, Aleksander Skotnicki, Wojciech Baran, Maria Adamczyk-Cioch, Agata Wrzesien-Kus, Krystyna Jagoda
Journal: Blood (2004)
SAT0562 Comparison of MRI and Radiography in Detecting Structural Damage of The Sacroiliac Joints in Patients with Chronic Low Back Pain Using Low-Dose CT as Standard of Reference – Results from The Simact Study
Authors: T. Diekhoff, J. Greese, J. Sieper, K.-G.A. Hermann
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The ability of magnetic resonance imaging (MRI) to detect structural changes of the sacroiliac joint (SIJ) is subject to discussion, whereas radiography as established method provides poor reliability. <h3>Objectives</h3> The aim of this study was to compare the ability of MRI and radiography in detecting erosions, sclerosis, pseudowidening and ankylosis of the SIJ using low dose computed tomography (ldCT) as standard of reference. <h3>Methods</h3> We prospectively included 110 patients in the study. All patients underwent a ldCT (Somatom Definition Flash, Siemens, Germany) and an MRI (3.0T Magnetom Skyra, Siemens, Germany) including a paracoronal T1 sequence of the SI-joints. Imaging data were compared with X-ray of the pelvis. Two readers independently scored the datasets for the presence of erosions, sclerosis and changes of the joint space in a blinded fashion using a comprehensive scoring system. Contingency table analysis was performed using ldCT as standard of reference. Inter-rater reliability was calculated using Cohen9s kappa. The agreement of all modalities with the expert rheumatologists diagnosis was calculated for three diagnostic categories (axSpA, mechanical back pain, normal). <h3>Results</h3> We found following sensitivity and specificity for the detection of structural lesions on patient9s level: erosions (0.42/0.86 for radiography, 0.79/0.93 for MRI), sclerosis (0.7/0.9 radiography, 0.3/0.96 MRI) and joint space alterations (0.41/0.95 radiography, 0.76/0.99 MRI), respectively. Inter-rater reliability was fair for radiography (0.32 to 0.4) and substantial for MRI (0.35 to 0.62) and ldCT (0.5 to 0.7) with the poorest reliability for sclerosis each. Diagnostic accuracy ranged from 0.41 to 0.52 for radiography, 0.62 to 0.72 for MRI and 0.63 to 0.75 for ldCT. <h3>Conclusions</h3> MRI is superior to radiography in detecting erosions and alterations of the joint space, however, inferior in detecting sclerosis. Most reliable diagnostic parameters amongst all imaging modalities were erosions and joint space alterations. Cross-sectional imaging modalities, including MRI, provide a superior diagnostic accuracy compared to conventional radiography. <h3>Acknowledgement</h3> The authors thank the Assessment of Spondyloarthritis international Society (ASAS) for supporting the study with a research grant. <h3>Disclosure of Interest</h3> None declared
Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis
Authors: Erin E. Mulvihill, Elodie M. Varin, Bojana Gladanac, Jonathan E. Campbell, John R. Ussher, Laurie L. Baggio, Bernardo Yusta, Jennifer Ayala, Melissa A. Burmeister, Dianne Matthews, K.W. Annie Bang, Julio E. Ayala, Daniel J. Drucker
Journal: Cell Metabolism (2016)
OP0150 3-Bromopyruvate Ameliorates Autoimmune Arthritis by Exerting A Dual Effect on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation
Authors: T. Okano, J. Saegusa, K. Nishimura, S. Takahashi, S. Sendo, Y. Ueda, A. Onishi, A. Morinobu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Recent studies have shown that cellular metabolism plays an important role in regulating immune cell function. In the process of cell differentiation, both interleukin-17-producing T (Th17) cells and dendritic cells (DCs) show increase of glycolytic activity by upregulating glycolytic enzymes, such as hexokinase-II (HK-II). Blocking glycolysis by 2-deoxyglucose has recently been demonstrated to inhibit Th17 cell differentiation while promote regulatory T (Treg) cell generation, and then ameliorate experimental autoimmune encephalitis model. <h3>Objectives</h3> The aim of this study is to verify the effect of 3-bromopyruvate (BrPA), a specific inhibitor of HK-II, on the differentiation and function of immune cells and on experimental arthritis in SKG mice. <h3>Methods</h3> Arthritis was induced in SKG mice by Zymosan A injection. BrPA (5 mg/kg) was administered subcutaneously once daily. CD4+ T cells from splenocytes of unimmunized SKG mice were cultured with anti-CD3/anti-CD28, anti-IFN-γ, anti-IL-4, IL-6, TGF-β, and IL-2, with or without BrPA for 5 days, and then analyzed by flow cytometry. Bone marrow (BM) cells from unimmunized SKG mice were cultured with GM-CSF and IL-4 (for 3 days), and with LPS (for 1 day) with or without BrPA, and then analyzed by flow cytometry. <h3>Results</h3> Treatment with BrPA significantly ameliorated arthritis of SKG mice (Figure). Histological scores of arthritis in BrPA-treated mice were significantly reduced compared with those in control mice. Flow cytometric analysis revealed that significant increase of Treg cells, decrease of Th17 cells, and decrease of CD40+CD86+CD11b+CD11c+ activated DCs were observed in the splenocytes from BrPA-treated mice. BrPA did not affect IFN-γ-producing Th1 cells nor IL-4-producing Th2 cells. <i>In vitro</i>, BrPA facilitated the differentiation of Treg cells, while it inhibited the development of Th17 cells. In addition, treatment of BM cells with BrPA inhibited the differentiation of activated DCs and the production of TNF-α and IL-6 from DCs. <h3>Conclusions</h3> BrPA facilitates the differentiation of Treg cells, and inhibits the development of Th17 cells and the activation of DCs, and ameliorates arthritis in the SKG mice. <h3>Disclosure of Interest</h3> None declared
SAT0235 Survival in Systemic Sclerosis Related Pulmonary Arterial Hypertension in The Modern Treatment Era: Results from A Multicentre Australian Cohort Study: Table 1.
Authors: K. Morrisroe, M. Huq, W. Stevens, C. Rabusa, S. Proudman, M. Nikpour
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pulmonary arterial hypertension (PAH) is the leading cause of mortality in patients with systemic sclerosis (SSc). <h3>Objectives</h3> To determine the cumulative survival rates and predictors of mortality in SSc- PAH <h3>Methods</h3> Patients enrolled in a SSc longitudinal cohort between 2007 and 2015 were included. PAH was diagnosed on right heart catheterization (RHC) (mPAP &gt;25 and PAWP &lt;15 mmHg). Patients with pulmonary hypertension secondary to interstitial lung disease (ILD) and co-existent PAH and severe interstitial lung disease (ILD) (defined as a HRCT scan demonstrating ILD with a FVC&lt;60%) were excluded. Summary statistics, chi-square tests and survival methods including Kaplan-Meier survival curves and cox proportional hazards regression were used to determine survival rates and identify predictors of mortality. <h3>Results</h3> Among 132 SSc PAH, 84.9% were female, 68.9% had limited disease subtype (lcSSc), the mean age at diagnosis of PAH was 62.3 years and disease duration at PAH diagnosis was 14.1 years. Over a median follow-up of 3.7 years, 60 (45.5%) patients died with a median survival time from PAH diagnosis of 3.7 years. The standardized mortality ratio for patients with SSc-PAH compared with mortality in the general population is 5.8 (95%CI 4.3–7.8). The years of life lost overall for both males and females due to SSc-PAH was 15.22 years (95%CI 12.3–18.1). Kaplan-Meier survival curves showed a survival advantage with combination therapy and anticoagulation. In cox proportional hazards regression analysis (table1), older age at PAH diagnosis, presence of mild ILD, worse WHO functional class, higher mean pulmonary arterial pressure at PAH diagnosis and presence of digital ulcers were predictive of PAH mortality. Combination PAH therapy together with anticoagulation, provided the most significant survival advantage with a 72% reduction in mortality compared with pulmonary vasodilator therapy alone. <h3>Conclusions</h3> Despite advanced therapy, the median survival in SSc PAH is only 4 years. In our study, the addition of anticoagulation to standard combination therapy was associated with a significant survival advantage, pointing to mechanisms involving endothelial abnormalities and small vessel thrombosis in the pathogenesis of PAH. <h3>Disclosure of Interest</h3> None declared
FRI0218 Safety of Non Anti-TNF Biologic Agents in Rheumatic Patients with Past Hepatitis B Virus Infection. A Single-Center Real-Life Study
Authors: I. Papalopoulos, N. Kougkas, N. Avgoustidis, A. Repa, A. Fanouriakis, P. Sidiropoulos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The safety of newer non anti-TNF biologic agents [abatacept (ABA), tocilizumab (TCZ) and rituximab (RTX)] in patients with autoimmune rheumatic diseases and past HBV infection [defined as HBsAg(−), anti-HBc(+), anti-HBs(±)] has not been firmly established. <h3>Objectives</h3> To assess the safety [reactivation of hepatitis B virus (HBV)] of non anti-TNF biologic agents in patients with serologic evidence of past HBV infection in real-life clinical settings. <h3>Methods</h3> Retrospective chart review of patients followed in the Department of Rheumatology of the University Hospital of Crete. Patients who received ABA, TCZ or RTX during the period 2005–2015 and were HBsAg(−), anti-HBc(+), anti-HBs(±) at baseline were identified and reviewed for cases of HBV reactivation (defined as increased ALT accompanied by an increase of serum HBV DNA levels by &gt;1 log<sub>10</sub> compared with baseline or a switch in HBV DNA detection from negative to positive). Changes in anti-HBs titers during biologic therapy in patients who were anti-HBs(+) at baseline were also documented. <h3>Results</h3> 83 different cases of non anti-TNF biologic therapy (34 ABA, 26 RTX and 23 TCZ) from 58 patients (56 RA - 2 ANCA-associated vasculitis) were identified. 64 cases (77.1%) were anti-HBc(+) anti-HBs(+) and 19 (22.9%) were anti-HBc(+) anti-HBs(−). Mean (SD) age at disease diagnosis and at non anti-TNF initiation was 53.6 (13.1) and 63.4 (9.2) years, respectively. All cases with RA had received prior anti-TNF agents [mean (SD) number of anti-TNF agents 1.1 (0.8)]. During treatment with non anti-TNF, concomitant synthetic disease modifying drugs or glucocorticoids were received by 91.5% and 46.3% of cases, respectively. Only 7 cases (8.4%) received antiviral prophylaxis concomitant with non anti-TNF treatment (4 with lamivudine - 3 with entecavir). After a mean (SD) of 41.9 (24.6) months of follow-up and a mean (SD) of 18.0 (15.9) therapy cycles, one anti-HBc(+) anti-HBs(−) case experienced HBV reactivation 12 months after treatment with abatacept and was treated with tenofovir with good outcome. Of anti-HBs(+) patients at baseline, titers of anti-HBs antibodies did not show statistically significant delay from baseline to most recent follow-up (456.9 mIU/ml vs. 390.7 mIU/ml, respectively, p=0.08) (Figure 1). <h3>Conclusions</h3> One case of HBV reactivation underlines the need for diligent monitoring in patients with serologic evidence of past HBV infection receiving non anti-TNF biologic agents. More data are needed to determine the need for universal prophylactic antiviral therapy in this subset of patients. <h3>Disclosure of Interest</h3> None declared
Involvement of ERK, p38 and NFκB Signalling in the Maturation Defects of Monocyte Derived Dendritic Cells in Patients with Myelodysplastic Syndrome.
Authors: Ilina Micheva, Panos Ziros, Lorna Pherson, Nikolaos Giannakoulas, Argiris Symeonidis, Nicholas Zoumbos
Journal: Blood (2005)
AB0555 Amount of Proteinuria Is Risk of Flare from Bvas Remission among Microscopic Polyangiitis Patients in Japan
Authors: M. Watanabe, Y. Fujita, H. Shimizu, M. Terashita, Y. Haji
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Microscopic polyangiitis (MPA) is a common form of ANCA associated vasculitis in Japan. Renal involvement is frequent in MPA and an important factor with respect to therapeutic methods and outcomes. <h3>Objectives</h3> To determine the association between renal characteristics at diagnosis and the relapse. <h3>Methods</h3> A retrospective review was conducted in 28 patients who were newly diagnosed as MPA. (January 2007 to August 2015) Baseline characteristics are collected include urine profile and renal pathology. The primary endpoint is the first flare. Disease flare is defined an increase in at least one major Birmingham vasculitis activity score (BVAS) items. Furthermore, analysis on other outcomes, such as end stage renal failure, induction of hemodialysis and death has been conducted. <h3>Results</h3> Of the 28 patients with MPA, all patients had renal vasculitis. 18 achieved BVAS remission, and relapse occurred among 5 patients (19.2%). Cox multivariate analysis showed that amount of proteinuria on admission was a predictor of relapse (HR 4.2; 95% CI, 0.13–10.5). In renal biopsy, those relapsed five cases tend to have more intensive glomerulonephritis, according to the European Vasculitis Study Group (EUVAS) classification, though no statistical significance was performed. <h3>Conclusions</h3> Amount of proteinuria is a risk factor for relapse in MPA. <h3>References</h3> Suppiah R et al. A cross- sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology. 2011;50: 899–905 Tarzi, R. M. et al. Issues in trial design for ANCA-associated and large-vessel vasculitis. Nature Review Rheumatology. 2014;10: 502–510 EBerden AE et al. Histopathological classification of ANCA-associated glomerulonephritis. Journal of American Society of Nephrology. 2010;10:1628–36 <h3>Disclosure of Interest</h3> None declared
Difference of Allo-Immunity to Erythrocytes in Asian Countries: Cooperative Study of Allo-Immunity to Antigen Diversity in Asian Population.
Authors: Hiroko Watanabe, Akihiro Takeshita, Dae Won Kim, So Yong Kwon, Kyou Sup Han, Jang Soo Suh, Chan Pui Ha Natalie, Veera Sekaran Nadarajan, Parichart Permpikul, Nuranissa Bte Yacob Marican, Makoto Uchikawa, Shuichi Kino, Hitoshi Ohto
Journal: Blood (2009)